Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04877522 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04877522 · ClinicalTrials.gov record · last posted 2026-07-06

Asciminib Roll-over Study

Name: Asciminib Roll-over Study — clinical trial record (NCT04877522)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorNovartis Pharmaceuticals

Started2022-08-30

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

Amendment record 53 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 53 times since 2021-05-04; most recent amendment 2026-07-01. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-08-17

Status change Not Yet Recruiting→Recruitingv7

Trial Details

NCT Number	NCT04877522
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enrollment	347 participants
Start Date	2022-08-30
Primary Completion	2030-08-30 (estimated)
Study Completion	2030-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-06